Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharma Mar SA ( (ES:PHM) ) has provided an announcement.
Pharma Mar has reported the latest activity under its liquidity contract with JB Capital Markets, detailing transactions in its own shares between March 30 and March 31, 2026. The program, originally launched in 2021 and recently resumed following a treasury share acquisition, is designed to promote liquidity and regularity in the trading of the company’s stock.
During the reported two-day period, the company executed both purchases and sales of its shares, resulting in a net decrease in the number of treasury shares but an increase in the total cash position associated with the liquidity account. These operations underscore Pharma Mar’s ongoing use of regulated liquidity mechanisms to support its market presence, which can help reduce volatility and improve trading conditions for shareholders.
The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR104.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.
More about Pharma Mar SA
Pharma Mar S.A. is a Spanish biopharmaceutical company focused on oncology and other specialized therapies, with its shares listed on the Spanish stock market. The company actively manages its share liquidity and treasury stock through market operations, aiming to support orderly trading and price stability for its investors.
Average Trading Volume: 48,064
Technical Sentiment Signal: Strong Buy
Current Market Cap: €1.52B
For a thorough assessment of PHM stock, go to TipRanks’ Stock Analysis page.